A detailed history of Blair William & CO transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Blair William & CO holds 12,952 shares of EGRX stock, worth $8,418. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,952
Previous 13,100 1.13%
Holding current value
$8,418
Previous $73,000 34.25%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.71 - $6.07 $549 - $898
-148 Reduced 1.13%
12,952 $48,000
Q2 2024

Aug 12, 2024

SELL
$3.34 - $5.6 $3,507 - $5,880
-1,050 Reduced 7.42%
13,100 $73,000
Q1 2024

May 09, 2024

SELL
$4.26 - $6.51 $13,695 - $20,929
-3,215 Reduced 18.51%
14,150 $74,000
Q4 2023

Feb 12, 2024

SELL
$4.63 - $15.21 $23,543 - $77,342
-5,085 Reduced 22.65%
17,365 $90,000
Q3 2023

Nov 09, 2023

SELL
$15.21 - $22.88 $27,758 - $41,756
-1,825 Reduced 7.52%
22,450 $354,000
Q2 2023

Aug 11, 2023

SELL
$17.74 - $31.87 $41,688 - $74,894
-2,350 Reduced 8.83%
24,275 $471,000
Q1 2023

May 12, 2023

SELL
$25.06 - $34.09 $314,427 - $427,727
-12,547 Reduced 32.03%
26,625 $755,000
Q4 2022

Feb 10, 2023

SELL
$24.98 - $39.77 $79,561 - $126,667
-3,185 Reduced 7.52%
39,172 $1.14 Million
Q2 2022

Aug 10, 2022

SELL
$41.26 - $51.35 $825 - $1,027
-20 Reduced 0.05%
42,357 $1.88 Million
Q1 2022

May 13, 2022

SELL
$44.58 - $52.6 $362,212 - $427,375
-8,125 Reduced 16.09%
42,377 $2.1 Million
Q4 2021

Feb 14, 2022

SELL
$45.82 - $56.9 $60,711 - $75,392
-1,325 Reduced 2.56%
50,502 $2.57 Million
Q3 2021

Nov 12, 2021

SELL
$43.79 - $55.78 $94,586 - $120,484
-2,160 Reduced 4.0%
51,827 $2.89 Million
Q2 2021

Aug 12, 2021

SELL
$36.86 - $44.5 $189,829 - $229,175
-5,150 Reduced 8.71%
53,987 $2.31 Million
Q1 2021

May 13, 2021

BUY
$40.32 - $50.97 $380,298 - $480,749
9,432 Added 18.98%
59,137 $2.47 Million
Q4 2020

Feb 09, 2021

BUY
$41.72 - $51.34 $25,741 - $31,676
617 Added 1.26%
49,705 $2.32 Million
Q3 2020

Nov 06, 2020

SELL
$37.02 - $51.28 $158,889 - $220,093
-4,292 Reduced 8.04%
49,088 $2.09 Million
Q2 2020

Aug 12, 2020

BUY
$43.24 - $55.02 $2,162 - $2,751
50 Added 0.09%
53,380 $2.56 Million
Q1 2020

May 11, 2020

SELL
$34.37 - $60.07 $180,098 - $314,766
-5,240 Reduced 8.95%
53,330 $2.45 Million
Q4 2019

Feb 13, 2020

SELL
$54.32 - $64.31 $108,911 - $128,941
-2,005 Reduced 3.31%
58,570 $3.52 Million
Q3 2019

Nov 12, 2019

BUY
$53.25 - $59.98 $44,517 - $50,143
836 Added 1.4%
60,575 $3.43 Million
Q2 2019

Aug 13, 2019

SELL
$46.61 - $58.45 $67,584 - $84,752
-1,450 Reduced 2.37%
59,739 $3.33 Million
Q1 2019

May 14, 2019

BUY
$38.66 - $51.82 $5,798 - $7,773
150 Added 0.25%
61,189 $3.09 Million
Q4 2018

Feb 14, 2019

SELL
$36.72 - $67.73 $393,087 - $725,049
-10,705 Reduced 14.92%
61,039 $2.46 Million
Q3 2018

Nov 13, 2018

SELL
$66.65 - $83.86 $11,663 - $14,675
-175 Reduced 0.24%
71,744 $4.97 Million
Q2 2018

Aug 13, 2018

SELL
$51.25 - $76.62 $151,187 - $226,029
-2,950 Reduced 3.94%
71,919 $5.44 Million
Q1 2018

May 15, 2018

SELL
$52.16 - $66.86 $196,121 - $251,393
-3,760 Reduced 4.78%
74,869 $3.95 Million
Q4 2017

Feb 14, 2018

BUY
$49.6 - $60.87 $349,878 - $429,376
7,054 Added 9.86%
78,629 $4.2 Million
Q3 2017

Nov 13, 2017

BUY
$46.62 - $60.36 $3.34 Million - $4.32 Million
71,575
71,575 $4.27 Million

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $8.46M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.